1Buy.AI | $3,900,000 | (Feb 3, 2026)
PranaX | $17,000,000 | (Feb 3, 2026)
DexMat | $5,000,000 | (Feb 3, 2026)
Certified by Founder
Lodge
OrsoBio
start up
United States
- Palo Alto, CA
- 08/11/2023
- Series A
- $60,000,000
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
- Industry Biotechnology Research
- Website https://orsobio.com/
- LinkedIn https://www.linkedin.com/company/orsobio/about/
Prenosis | $20,000,000 | (Feb 3, 2026)
CloudForge AI | $3,950,000 | (Feb 3, 2026)
Linq | $20,000,000 | (Feb 3, 2026)
Breezy | $10,000,000 | (Feb 3, 2026)
Poetiq | $45,800,000 | (Feb 3, 2026)
JJG Machining Group | $30,000,000 | (Feb 3, 2026)
Principle | $2,000,000 | (Feb 3, 2026)
BizTrip AI | $1,500,000 | (Feb 3, 2026)
Co-reactive | $7,754,157 | (Jan 30, 2026)